CL2019003459A1 - Métodos de cultivo celular. - Google Patents

Métodos de cultivo celular.

Info

Publication number
CL2019003459A1
CL2019003459A1 CL2019003459A CL2019003459A CL2019003459A1 CL 2019003459 A1 CL2019003459 A1 CL 2019003459A1 CL 2019003459 A CL2019003459 A CL 2019003459A CL 2019003459 A CL2019003459 A CL 2019003459A CL 2019003459 A1 CL2019003459 A1 CL 2019003459A1
Authority
CL
Chile
Prior art keywords
recombinant protein
weight
cell culture
total
produced
Prior art date
Application number
CL2019003459A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Jeffrey Yates
Yahia Bassem Ben
Laetitia Malphettes
Nadine Kochanowski
Gill Renner
Sandrine Durran
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59270991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019003459(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CL2019003459A1 publication Critical patent/CL2019003459A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CL2019003459A 2017-05-31 2019-11-26 Métodos de cultivo celular. CL2019003459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1708655.4A GB201708655D0 (en) 2017-05-31 2017-05-31 Cell culture methods

Publications (1)

Publication Number Publication Date
CL2019003459A1 true CL2019003459A1 (es) 2020-04-24

Family

ID=59270991

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003459A CL2019003459A1 (es) 2017-05-31 2019-11-26 Métodos de cultivo celular.

Country Status (21)

Country Link
US (3) US12077796B2 (https=)
EP (2) EP3630946B1 (https=)
JP (3) JP7460370B2 (https=)
KR (3) KR20200012972A (https=)
CN (2) CN119326882A (https=)
AU (2) AU2018276376C1 (https=)
BR (1) BR112019024390A2 (https=)
CA (1) CA3065661A1 (https=)
CL (1) CL2019003459A1 (https=)
CO (1) CO2019012871A2 (https=)
EA (1) EA201992828A1 (https=)
ES (1) ES2978394T3 (https=)
GB (1) GB201708655D0 (https=)
HR (1) HRP20240585T1 (https=)
HU (1) HUE066922T2 (https=)
IL (2) IL270880B2 (https=)
MX (1) MX2019014140A (https=)
MY (1) MY193535A (https=)
PL (1) PL3630946T3 (https=)
RU (2) RU2021128024A (https=)
WO (1) WO2018219968A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
JP2023554489A (ja) * 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
GB202105424D0 (en) * 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes
WO2025262319A1 (en) 2024-06-21 2025-12-26 Boehringer Ingelheim International Gmbh Modifying blue color formation in bioprocesses

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
EP1623019B2 (en) 2003-05-15 2017-01-25 Wyeth LLC Restricted glucose feed for animal cell culture
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
SI2078071T1 (sl) * 2006-11-08 2015-05-29 Wyeth Llc Racionalno zasnovana gojišča za celično kulturo
US8030027B2 (en) * 2008-04-29 2011-10-04 St. Jude Children's Research Hospital Method for enhancing recombinant antibody production
US8252557B2 (en) 2008-10-28 2012-08-28 Chugai Seiyaku Kabushiki Kaisha Peptide-containing culture medium for culturing animal cell
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
RU2563353C2 (ru) 2010-04-26 2015-09-20 Новартис Аг Улучшенная среда для культивирования клеток
PL2563906T3 (pl) 2010-04-26 2018-04-30 Novartis Ag Sposób hodowli komórek cho
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
WO2012145682A1 (en) * 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP4527855A3 (en) * 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
JP2016513478A (ja) * 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド 細胞培養培地及び抗体を産生する方法
CN106715707A (zh) 2014-06-18 2017-05-24 免疫医疗公司 包含n‑乙酰半胱氨酸的细胞培养方法和培养基
WO2016108765A1 (en) 2014-12-29 2016-07-07 Wirojpaisi Wanlop Engine combustion system oxygen efficiency enhancing device with raised electrical voltage and improved installation method
GB201508180D0 (en) * 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
KR102425040B1 (ko) 2016-04-28 2022-07-25 메르크 파텐트 게엠베하 단백질 내 트리술파이드 수준을 감소시키기 위한 방법
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
WO2018018613A1 (zh) * 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN106222129A (zh) 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods

Also Published As

Publication number Publication date
IL270880A (en) 2020-01-30
CN110741077B (zh) 2024-10-11
MY193535A (en) 2022-10-18
JP2022153421A (ja) 2022-10-12
RU2758674C2 (ru) 2021-11-01
JP7460370B2 (ja) 2024-04-02
EP3630946B1 (en) 2024-03-27
WO2018219968A1 (en) 2018-12-06
IL317828A (en) 2025-02-01
IL270880B2 (en) 2025-05-01
EP4397682A3 (en) 2024-08-21
AU2018276376C1 (en) 2025-01-30
HRP20240585T1 (hr) 2024-07-19
RU2021128024A (ru) 2021-12-08
EA201992828A1 (ru) 2020-04-21
RU2019143742A (ru) 2021-06-30
HUE066922T2 (hu) 2024-09-28
AU2024259881A1 (en) 2024-11-28
BR112019024390A2 (pt) 2020-07-14
CN110741077A (zh) 2020-01-31
JP7406593B2 (ja) 2023-12-27
EP4397682A2 (en) 2024-07-10
CO2019012871A2 (es) 2020-01-17
PL3630946T3 (pl) 2024-07-01
JP2020521490A (ja) 2020-07-27
GB201708655D0 (en) 2017-07-12
AU2018276376A1 (en) 2019-12-12
JP7560420B2 (ja) 2024-10-02
AU2018276376B2 (en) 2024-08-15
JP2021185185A (ja) 2021-12-09
IL270880B1 (en) 2025-01-01
AU2024259881B2 (en) 2025-02-13
MX2019014140A (es) 2020-02-07
KR20200012972A (ko) 2020-02-05
ES2978394T3 (es) 2024-09-11
KR20250156183A (ko) 2025-10-31
US20250051824A1 (en) 2025-02-13
CN119326882A (zh) 2025-01-21
EP3630946C0 (en) 2024-03-27
EP3630946A1 (en) 2020-04-08
US12077796B2 (en) 2024-09-03
RU2019143742A3 (https=) 2021-06-30
CA3065661A1 (en) 2018-12-06
US20250066832A1 (en) 2025-02-27
US20200239923A1 (en) 2020-07-30
KR20240096888A (ko) 2024-06-26

Similar Documents

Publication Publication Date Title
CL2019003459A1 (es) Métodos de cultivo celular.
BR112020015308A8 (pt) Proteínas f de rsv estabilizadas e usos das mesmas
EA201491155A1 (ru) Новые мутантные про-нрф и их применение для получения бета-нрф
EA201792441A2 (ru) Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
MX375911B (es) Constructos de anticuerpo multiespecifico.
CO2018001420A2 (es) Biomasa rica en proteína de traustoquitridios, método de cultivo y utilización
UY36475A (es) Composiciones y metodos para el uso de insecticida con bacillus sp d747
EA201270304A1 (ru) Способы получения шелковой пасты
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
EA202190326A3 (ru) Не содержащая сыворотки среда для культивирования клеток
ES2627117T3 (es) Método basado en MGMT para obtener un rendimiento elevado de expresión de proteínas recombinantes
AR089231A1 (es) Metodo de floculacion
EA202091349A1 (ru) Способы культивирования клеток
BR112016024911A2 (pt) composições de proteínas solúveis e métodos de sua produçâo
MX387420B (es) Producción de virus en cultivos celulares.
EA033293B1 (ru) Рекомбинантный микроорганизм, экспрессирующий аналог авермектина, и его применение
EA201691953A1 (ru) Белки тонопласта, функционирующие как протон/сахар-антипортеры, и их использование для повышения концентрации сахарозы в запасающем сахарозу органе растений
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
CO6592086A2 (es) Metodo para producir proteinas de interferon recombiantes solubles sin desnaturalizacion
MX393714B (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.
RU2013146452A (ru) Инъекционный или инфузионный раствор триазавирина для лечения вирусных инфекций
AR084596A1 (es) Produccion fermentativa de analogo de hidroximetionina (mha)